|
2018 Conference Publication Adjuvant therapy with nivolumab versus ipilimumab after complete resection of stage III/IV melanoma: Updated results from a phase 3 trial (CheckMate 238)Weber, Jeffrey S., Mandala, Mario, Del Vecchio, Michele, Gogas, Helen, Arance, Ana M., Cowey, C. Lance, Dalle, Stephane, Schenker, Michael, Chiarion-Sileni, Vanna, Marquez-Rodas, Ivan, Grob, Jean-Jacques, Butler, Marcus, Middleton, Mark R., Maio, Michele, Atkinson, Victoria, Dummer, Reinhard, de Pril, Veerle, Qureshi, Anila, Larkin, James and Ascierto, Paolo A. (2018). Adjuvant therapy with nivolumab versus ipilimumab after complete resection of stage III/IV melanoma: Updated results from a phase 3 trial (CheckMate 238). National-Cancer-Research-Institute (NCRI) Cancer Conference, Glasgow Scotland, Nov 04-06, 2018. LONDON: NATURE PUBLISHING GROUP. |
|
2018 Conference Publication ILLUMINATE 301: A randomized phase III comparison of IMO-2125 with ipilimumab (ipi) versus ipi alone in subjects with anti PD 1 refractory melanomaAscierto, P. A., Arenberger, P., Atkinson, V. G., Hansson, J., Kapiteijn, E., Loquai, C., Negrier, S., Shaw, H. M., Tarhini, A., Walker, J., Geib, J., Rahimian, S., Swann, S. and Diab, A. (2018). ILLUMINATE 301: A randomized phase III comparison of IMO-2125 with ipilimumab (ipi) versus ipi alone in subjects with anti PD 1 refractory melanoma. 43rd ESMO Congress (ESMO), Munich Germany, Oct 19-23, 2018. OXFORD: OXFORD UNIV PRESS. |
|
2018 Conference Publication Updated relapse-free survival (RFS) and biomarker analysis in the COMBI-AD trial of adjuvant dabrafenib + trametinib (D + T) in patients (pts) with resected BRAF V600-mutant stage III melanomaLong, G. V., Hauschild, A., Santinami, M., Atkinson, V. G., Mandala, M., Chiarion-Sileni, V., Larkin, J., Robert, C., Schadendorf, D., Dasgupta, K., Shilkrut, M., Garrett, J., Brase, J. C., Kefford, R., Kirkwood, J. M. and Dummer, R. (2018). Updated relapse-free survival (RFS) and biomarker analysis in the COMBI-AD trial of adjuvant dabrafenib + trametinib (D + T) in patients (pts) with resected BRAF V600-mutant stage III melanoma. 43rd ESMO Congress (ESMO 2018), Munich, Germany, 19-23 October 2018. Amsterdam, Netherlands: Elsevier. doi: 10.1093/annonc/mdy424.053 |
|
2018 Conference Publication CA224-047: A randomized, double-blind, phase II/III study of relatlimab (anti-LAG-3) in combination with nivolumab (anti-PD-1) versus nivolumab alone in previously untreated metastatic or unresectable melanomaLipson, E. J., Long, G. V., Tawbi, H., Schadendorf, D., Atkinson, V. G., Maurer, M., Simonsen, K. L., Harbison, C. and Hodi, F. S. (2018). CA224-047: A randomized, double-blind, phase II/III study of relatlimab (anti-LAG-3) in combination with nivolumab (anti-PD-1) versus nivolumab alone in previously untreated metastatic or unresectable melanoma. 43rd ESMO Congress (ESMO), Munich Germany, Oct 19-23, 2018. OXFORD: OXFORD UNIV PRESS. |
|
2018 Conference Publication ILLUMINATE 301: A randomized phase III comparison of IMO-2125 with ipilimumab (ipi) versus ipi alone in subjects with anti PD 1 refractory melanomaAscierto, P. A., Arenberger, P., Atkinson, V. G., Hansson, J., Kapiteijn, E., Loquai, C., Negrier, S., Shaw, H. M., Tarhini, A., Walker, J., Geib, J., Rahimian, S., Swann, S. and Diab, A. (2018). ILLUMINATE 301: A randomized phase III comparison of IMO-2125 with ipilimumab (ipi) versus ipi alone in subjects with anti PD 1 refractory melanoma. 43rd ESMO Congress (ESMO 2018), Munich, Germany, 19–23 October 2018. Amsterdam, Netherlands: Elsevier. doi: 10.1093/annonc/mdy289.062 |
|
2018 Conference Publication CA224-047: A randomized, double-blind, phase II/III study of relatlimab (anti-LAG-3) in combination with nivolumab (anti-PD-1) versus nivolumab alone in previously untreated metastatic or unresectable melanomaLipson, E. J., Long, G. V., Tawbi, H., Schadendorf, D., Atkinson, V. G., Maurer, M., Simonsen, K. L., Harbison, C. and Hodi, F. S. (2018). CA224-047: A randomized, double-blind, phase II/III study of relatlimab (anti-LAG-3) in combination with nivolumab (anti-PD-1) versus nivolumab alone in previously untreated metastatic or unresectable melanoma. 43rd ESMO Congress (ESMO 2018), Munich, Germany, 19–23 October 2018. Amsterdam, Netherlands: Elsevier. doi: 10.1093/annonc/mdy289.058 |
|
2018 Conference Publication Adverse events (AEs) over time in patients (pts) treated with adjuvant dabrafenib plus trametinib (D + T) or placebo (Pbo) in the COMBI-AD trialAtkinson, V. G., Hauschild, A., Santinami, M., Mandala, M., Chiarion Sileni, V., Larkin, J., Nyakas, M. S., Dutriaux, C., Haydon, A., Mortier, L., Robert, C., Schachter, J., Schadendorf, D., Feng, X., de Jong, E., Mookerjee, B., Kefford, R., Dummer, R., Kirkwood, J. M. and Long, G. V. (2018). Adverse events (AEs) over time in patients (pts) treated with adjuvant dabrafenib plus trametinib (D + T) or placebo (Pbo) in the COMBI-AD trial. 43rd ESMO Congress (ESMO 2018), Munich, Germany, 19–23 October 2018. Amsterdam, Netherlands: Elsevier. doi: 10.1093/annonc/mdy289.007 |
|
2018 Conference Publication Adverse events (AEs) over time in patients (pts) treated with adjuvant dabrafenib plus trametinib (D plus T) or placebo (Pbo) in the COMBI-AD trialAtkinson, V. G., Hauschild, A., Santinami, M., Mandala, M., Sileni, V. Chiarion, Larkin, J., Nyakas, M. S., Dutriaux, C., Haydon, A., Mortier, L., Robert, C., Schachter, J., Schadendorf, D., Feng, X., de Jong, E., Mookerjee, B., Kefford, R., Dummer, R., Kirkwood, J. M. and Long, G. V. (2018). Adverse events (AEs) over time in patients (pts) treated with adjuvant dabrafenib plus trametinib (D plus T) or placebo (Pbo) in the COMBI-AD trial. 43rd ESMO Congress (ESMO), Munich Germany, Oct 19-23, 2018. OXFORD: OXFORD UNIV PRESS. |
|
2018 Conference Publication Estimate of long-term relapse-free survival (RFS) and analysis of baseline factors associated with RFS in the COMBI-AD trialDummer, R., Schadendorf, D., Hauschild, A., Santinami, M., Atkinson, V. G., Mandala, M., Sileni, V. Chiarion, Larkin, J., Nyakas, M. S., Dutriaux, C., Haydon, A., Mortier, L., Robert, C., Schachter, J., Feng, X., de Jong, E., Mookerjee, B., Kefford, R., Kirkwood, J. M. and Long, G. V. (2018). Estimate of long-term relapse-free survival (RFS) and analysis of baseline factors associated with RFS in the COMBI-AD trial. 43rd ESMO Congress (ESMO), Munich Germany, Oct 19-23, 2018. OXFORD: OXFORD UNIV PRESS. |
|
2018 Conference Publication Updated relapse-free survival (RFS) and biomarker analysis in the COMBI-AD trial of adjuvant dabrafenib plus trametinib (D plus T) in patients (pts) with resected BRAF V600-mutant stage III melanomaLong, G. V., Hauschild, A., Santinami, M., Atkinson, V. G., Mandala, M., Chiarion-Sileni, V., Larkin, J., Robert, C., Schadendorf, D., Dasgupta, K., Shilkrut, M., Garrett, J., Brase, J. C., Kefford, R., Kirkwood, J. M. and Dummer, R. (2018). Updated relapse-free survival (RFS) and biomarker analysis in the COMBI-AD trial of adjuvant dabrafenib plus trametinib (D plus T) in patients (pts) with resected BRAF V600-mutant stage III melanoma. 43rd ESMO Congress (ESMO), Munich Germany, Oct 19-23, 2018. OXFORD: OXFORD UNIV PRESS. |
|
2018 Conference Publication Estimate of long-term relapse-free survival (RFS) and analysis of baseline factors associated with RFS in the COMBI-AD trialDummer, R., Schadendorf, D., Hauschild, A., Santinami, M., Atkinson, V. G., Mandala, M., Chiarion Sileni, V., Larkin, J., Nyakas, M. S., Dutriaux, C., Haydon, A., Mortier, L., Robert, C., Schachter, J., Feng, X., de Jong, E., Mookerjee, B., Kefford, R., Kirkwood, J. M. and Long, G. V. (2018). Estimate of long-term relapse-free survival (RFS) and analysis of baseline factors associated with RFS in the COMBI-AD trial. 43rd ESMO Congress (ESMO 2018), Munich, Germany, 19–23 October 2018. Amsterdam, Netherlands: Elsevier. doi: 10.1093/annonc/mdy289.006 |
|
2018 Journal Article Omitting radiosurgery in melanoma brain metastases: a drastic and dangerous de-escalationLong, Georgina V., Atkinson, Victoria, Hong, Angela, McArthur, Grant A. and Menzies, Alexander M. (2018). Omitting radiosurgery in melanoma brain metastases: a drastic and dangerous de-escalation. Lancet Oncology, 19 (8), E367-E367. doi: 10.1016/S1470-2045(18)30508-4 |
|
2018 Journal Article The changing paradigm of management in melanoma brain metastasesLadwa, Rahul and Atkinson, Victoria (2018). The changing paradigm of management in melanoma brain metastases. Asia Pacific Journal of Clinical Oncology, 14 (6), 453-458. doi: 10.1111/ajco.12998 |
|
2018 Journal Article Neoadjuvant chemotherapy or chemoradiotherapy for adenocarcinoma of the esophagusVisser, Els, Edholm, David, Smithers, B. Mark, Thomson, Iain G., Burmeister, Bryan H., Walpole, Euan T., Gotley, David C., Joubert, Warren L., Atkinson, Victoria, Mai, Tao, Thomas, Janine M. and Barbour, Andrew P. (2018). Neoadjuvant chemotherapy or chemoradiotherapy for adenocarcinoma of the esophagus. Journal of Surgical Oncology, 117 (8), 1687-1696. doi: 10.1002/jso.25089 |
|
2018 Journal Article Adjuvant pembrolizumab versus placebo in resected stage III melanomaEggermont, Alexander M. M., Blank, Christian U., Mandala, Mario, Long, Georgina V., Atkinson, Victoria, Dalle, Stéphane, Haydon, Andrew, Lichinitser, Mikhail, Khattak, Adnan, Carlino, Matteo S., Sandhu, Shahneen, Larkin, James, Puig, Susana, Ascierto, Paolo A., Rutkowski, Piotr, Schadendorf, Dirk, Koornstra, Rutger, Hernandez-Aya, Leonel, Maio, Michele, van den Eertwegh, Alfonsus J. M., Grob, Jean-Jacques, Gutzmer, Ralf, Jamal, Rahima, Lorigan, Paul, Ibrahim, Nageatte, Marreaud, Sandrine, van Akkooi, Alexander C. J., Suciu, Stefan and Robert, Caroline (2018). Adjuvant pembrolizumab versus placebo in resected stage III melanoma. The New England Journal of Medicine, 378 (19), 1789-1801. doi: 10.1056/NEJMoa1802357 |
|
2018 Journal Article Combination nivolumab and ipilimumab or nivolumab alone in melanoma brain metastases: a multicentre randomised phase 2 studyLong, Georgina V., Atkinson, Victoria, Lo, Serigne, Sandhu, Shahneen, Guminski, Alexander D., Brown, Michael P., Wilmott, James S., Edwards, Jarem, Gonzalez, Maria, Scolyer, Richard A., Menzies, Alexander M. and McArthur, Grant A. (2018). Combination nivolumab and ipilimumab or nivolumab alone in melanoma brain metastases: a multicentre randomised phase 2 study. The Lancet Oncology, 19 (5), 672-681. doi: 10.1016/S1470-2045(18)30139-6 |
|
2018 Journal Article Focal regression of a primary melanoma, fading lentigines, and poliosis in metastatic melanoma treated with anti-PD-1Thomas, S, Laino, A, Sturm, R, Nufer, K, Lambie, D, Shepherd, B, Atkinson, V, Adams, L, Soyer, H P and Schaider, H (2018). Focal regression of a primary melanoma, fading lentigines, and poliosis in metastatic melanoma treated with anti-PD-1. Journal of the European Academy of Dermatology and Venereology : JEADV, 32 (5), e176-e177. doi: 10.1111/jdv.14678 |
|
2018 Journal Article Acetylsalicylic acid governs the effect of sorafenib in RAS- mutant cancersHammerlindl, Heinz, Ravindran Menon, Dinoop, Hammerlindl, Sabrina, Emran, Abdullah Al, Torrano, Joachim, Sproesser, Katrin, Thakkar, Divya, Xiao, Min, Atkinson, Victoria G., Gabrielli, Brian, Haass, Nikolas K., Herlyn, Meenhard, Krepler, Clemens and Schaider, Helmut (2018). Acetylsalicylic acid governs the effect of sorafenib in RAS- mutant cancers. Clinical Cancer Research, 24 (5), 1090-1102. doi: 10.1158/1078-0432.CCR-16-2118 |
|
2018 Journal Article Survival Outcomes in Patients with Previously Untreated BRAF Wild-Type Advanced Melanoma Treated with Nivolumab Therapy: Three-Year Follow-up of a Randomized Phase 3 TrialAscierto, Paolo A., Long, Georgina V., Robert, Caroline, Brady, Benjamin, Dutriaux, Caroline, Di Giacomo, Anna Maria, Mortier, Laurent, Hassel, Jessica C., Rutkowski, Piotr, McNeil, Catriona, Kalinka-Warzocha, Ewa, Savage, Kerry J., Hernberg, Micaela M., Lebbé, Celeste, Charles, Julie, Mihalcioiu, Catalin, Chiarion-Sileni, Vanna, Mauch, Cornelia, Cognetti, Francesco, Ny, Lars, Arance, Ana, Svane, Inge Marie, Schadendorf, Dirk, Gogas, Helen, Saci, Abdel, Jiang, Joel, Rizzo, Jasmine and Atkinson, Victoria (2018). Survival Outcomes in Patients with Previously Untreated BRAF Wild-Type Advanced Melanoma Treated with Nivolumab Therapy: Three-Year Follow-up of a Randomized Phase 3 Trial. JAMA Oncology, 5 (2), 187-194. doi: 10.1001/jamaoncol.2018.4514 |
|
2017 Journal Article Pooled analysis safety profile of nivolumab and ipilimumab combination therapy in patients with advanced melanomaSznol, Mario, Ferrucci, Pier Francesco, Hogg, David, Atkins, Michael B., Wolter, Pascal, Guidoboni, Massimo, Lebbé, Celeste, Kirkwood, John M., Schachter, Jacob, Daniels, Gregory A., Hassel, Jessica, Cebon, Jonathan, Gerritsen, Winald, Atkinson, Victoria, Thomas, Luc, McCaffrey, John, Power, Derek, Walker, Dana, Bhore, Rafia, Jiang, Joel, Hodi, F. Stephen and Wolchok, Jedd D. (2017). Pooled analysis safety profile of nivolumab and ipilimumab combination therapy in patients with advanced melanoma. Journal of Clinical Oncology, 35 (34), 3815-3822. doi: 10.1200/JCO.2016.72.1167 |
